Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
June 24, 2024
Beyond Air® Appoints David Webster as Chief Commercial Officer
June 13, 2024
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
June 3, 2024
Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast
May 23, 2024
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
May 1, 2024
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
March 20, 2024
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
February 12, 2024
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
January 18, 2024
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
December 27, 2023
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe